Fig. 1 · Structure

Documents & Downloads

Caftaric acid

Cat. No. A12025 CAS 67879-58-7
Caftaric acid is a non-flavanoid that impacts the color of white wine.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Caftaric acid Research Summary

This section summarizes 1 in vitro study and 2 in vivo studies of Caftaric acid from 2 published references. In vitro models include isolated perfused rat liver model.

Caftaric acid In Vitro Studies

Caftaric acid supplementation was evaluated in an isolated perfused rat liver model subjected to static cold storage followed by reperfusion. Supplemented livers exhibited significantly lower perfusate ALT, AST, and LDH levels than vehicle controls. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Perfusate enzymes after cold storage and reperfusion

Cell-based study · isolated perfused rat liver model [1]

In an isolated perfused rat liver model, Caftaric acid-supplemented livers underwent static cold storage followed by reperfusion. Perfusate ALT, AST, and LDH levels were significantly lower than in the vehicle control group.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
AST, ALT and LDH in perfusate samplesReported result 50 µM; After 48 h of SCS followed by 2 h of reperfusion, perfusates from CA-supplemented livers exhibited significantly lower levels of ALT, AST, and LDH than those from the vehicle control group.[1]

Literature-Reported Treatment Conditions

Exposure duration
48 h of SCS followed by 2 h of reperfusion
Method
CA-supplemented livers
Co-treatment
Other interventions in this design: static cold storage (SCS) and reperfusion. Compound effect isolated by the comparison: vehicle control group.
Reported limits
Not stated in the sentences used: dose, vehicle.
Methods and source locations

Compound reported in the paper: Caftaric acid

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Caftaric Acid alleviates liver cold ischemia/reperfusion injury induced by extended cold ischemia time (S109, S113, S114, S121, S122)

AST, ALT and LDH in perfusate samples: AST, ALT and LDH in perfusate samples; comparator: vehicle control group — Results > Caftaric Acid alleviates liver cold ischemia/reperfusion injury induced by extended cold ischemia time (S109, S114, S122)

Caftaric acid In Vivo Studies

In male albino Sprague Dawley rats, intraperitoneal Caftaric acid was administered before METH injections. Serum AST and liver malondialdehyde were lower in the Caftaric acid + METH group than in the METH group. [2]

Serum AST in METH-injected rats

Animal study · Male albino (Sprague Dawley) rats; METH-injected rats; Number of animals = 8 per group. [2]

Male albino Sprague Dawley rats received intraperitoneal Caftaric acid before METH injections. Serum AST was lower in the Caftaric acid + METH group than in the METH group.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Serum aspartate aminotransferase (AST)AST 128.3 ± 3.94 U/L[2]

Conditions shared by the study groups

Route
injected once (i.p)
Treatment course
once; one day before METH injections
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Caftaric acid 40 mg/kgMETH groupCaftaric acid + METH group: 128.3 ± 3.94 U/L; METH group: 140.2 ± 0.72 U/L[2]
Caftaric acid 40 mg/kg
Model: Male albino (Sprague Dawley) rats; METH-injected rats; Number of animals = 8 per group.
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Caftaric acid

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

2. Materials and Methods > 2.1. Materials > 2.1.1. Animals (S4); 2. Materials and Methods > 2.1. Materials > 2.1.2. Experimental Design (S13); 2. Materials and Methods > 2.2. Methods > 2.2.1. Liver Function (S21); Figure 1 legend (S80); Figure 2 legend (S86); Table 1 legend (S87, S89); Table 1 (T1.h2, T1.r2, T1.r4)

Serum aspartate aminotransferase (AST): Serum aspartate aminotransferase (AST); comparator: METH group — 2. Materials and Methods > 2.2. Methods > 2.2.1. Liver Function (S21); Table 1 (T1.h2, T1.r2, T1.r4)

Caftaric acid 40 mg/kg · 2. Materials and Methods > 2.1. Materials > 2.1.2. Experimental Design (S13); Table 1 (T1.h2, T1.r2, T1.r4)

Liver malondialdehyde in METH-injected rats

Animal study · Male albino (Sprague Dawley) rats; METH-injected rats; Number of animals = 8 per group. [2]

Male albino Sprague Dawley rats received intraperitoneal Caftaric acid before METH injections. Liver malondialdehyde was lower in the Caftaric acid + METH group than in the METH group.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
liver malondialdehyde (MDA)MDA 34.25 ± 3.85 nmol/100 mg tissue[2]

Conditions shared by the study groups

Route
injected once (i.p)
Treatment course
once; one day before METH injections
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Caftaric acid 40 mg/kgMETH groupCaftaric acid + METH group: 34.25 ± 3.85 nmol/100 mg tissue; METH group: 56.85 ± 4.15 nmol/100 mg tissue[2]
Caftaric acid 40 mg/kg
Model: Male albino (Sprague Dawley) rats; METH-injected rats; Number of animals = 8 per group.
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Caftaric acid

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

2. Materials and Methods > 2.1. Materials > 2.1.1. Animals (S4); 2. Materials and Methods > 2.1. Materials > 2.1.2. Experimental Design (S13); 3. Results > 3.3. Antioxidants Enzymes (S57); Figure 1 legend (S80); Figure 2 legend (S86); Table 5 legend (S99, S101); Table 5 (T5.h2, T5.r2, T5.r4)

liver malondialdehyde (MDA): liver malondialdehyde (MDA); comparator: METH group — 3. Results > 3.3. Antioxidants Enzymes (S57); Table 5 (T5.h2, T5.r2, T5.r4)

Caftaric acid 40 mg/kg · 2. Materials and Methods > 2.1. Materials > 2.1.2. Experimental Design (S13); Table 5 (T5.h2, T5.r2, T5.r4)

Specifications

Manufacturer Adooq Bioscience
CAS Number 67879-58-7
Formula C13H12O9
Molecular Weight 312.23
SMILES
C1=CC(=C(C=C1/C=C/C(=O)O[C@H]([C@H](C(=O)O)O)C(=O)O)O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 88 mg/mL (281.84 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Caftaric acid Research References

  1. [1] Zhu Y, Li H, Li M, et al. Protective effect of Caftaric Acid against hepatic cold ischemia/reperfusion injury in the liver. Biol Direct (2026). PMID: 42087237 DOI: 10.1186/s13062-026-00826-z Source material
  2. [2] Koriem KM, Soliman RE. Chlorogenic and caftaric acids in liver toxicity and oxidative stress induced by methamphetamine. J Toxicol (2014). PMID: 25136360 DOI: 10.1155/2014/583494 Source material

Added to your cart

View Cart Checkout
Loading...